Theralink Technologies, Inc. (THER)
OTCMKTS
· Delayed Price · Currency is USD
0.0000
0.00 (0.00%)
At close: Apr 28, 2026
Theralink Technologies Revenue
Theralink Technologies had revenue of $83.95K in the quarter ending December 31, 2023, with 51.82% growth. This brings the company's revenue in the last twelve months to $635.45K, up 16.76% year-over-year. In the fiscal year ending September 30, 2023, Theralink Technologies had annual revenue of $606.80K with 6.85% growth.
Revenue (ttm)
635.45K
Revenue Growth
+16.76%
P/S Ratio
0.01
Revenue / Employee
39.72K
Employees
16
Market Cap
6.15K
Revenue Chart
Revenue History
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Therapeutic Solutions International | 85.32K |
| Syros Pharmaceuticals | 386.00K |
| Statera Biopharma | 3.69M |
| MultiCell Technologies | 805.24K |
| Bioasis Technologies | 199.01K |
Theralink Technologies News
- 2 years ago - Theralink announces groundbreaking RPPA study by partner GMU - reveals novel therapy options for hard-to-treat breast cancer patients that could lead to significant improvements in response rates - GlobeNewsWire
- 2 years ago - Theralink® and IMAC Holdings announce receipt and response to the Securities and Exchange Commission comments on the previously filed Form S4 - GlobeNewsWire
- 2 years ago - Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute's Molecular Tumor Board - GlobeNewsWire
- 2 years ago - Theralink Announces Filing of Form S-4; Merger with IMAC Holdings Expected During Q4 2023 - GlobeNewsWire
- 3 years ago - Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer - GlobeNewsWire
- 3 years ago - THERALINK INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Theralink Technologies, Inc. - THER - Business Wire
- 3 years ago - Theralink® Acquires Exclusive Landmark Immunotherapy Patent including Biomarker from Vanderbilt University - PRNewsWire
- 3 years ago - Theralink® Technologies Begins Receiving Payments from Third Party Payors for its Advanced Breast Cancer Assay, Achieving Key Milestone - PRNewsWire